Stryker Co. (SYK) Given Consensus Recommendation of “Buy” by Brokerages

Share on StockTwits

Stryker Co. (NYSE:SYK) has received a consensus rating of “Buy” from the twenty-three brokerages that are presently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $185.41.

A number of research firms recently issued reports on SYK. Credit Suisse Group upgraded shares of Stryker to an “outperform” rating in a research report on Thursday, January 31st. SunTrust Banks upped their price objective on shares of Stryker to $205.00 and gave the stock a “positive” rating in a research report on Monday, February 4th. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $199.00 price objective for the company in a research report on Monday, February 4th. Canaccord Genuity upped their price objective on shares of Stryker from $185.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, January 30th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research report on Friday, November 9th.

In other Stryker news, VP Bijoy Sagar sold 2,361 shares of the business’s stock in a transaction that occurred on Friday, December 7th. The shares were sold at an average price of $171.24, for a total transaction of $404,297.64. Following the sale, the vice president now directly owns 2,361 shares of the company’s stock, valued at approximately $404,297.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Michael Damon Hutchinson sold 10,109 shares of the business’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $180.14, for a total transaction of $1,821,035.26. The disclosure for this sale can be found here. Insiders have sold a total of 43,259 shares of company stock worth $7,515,747 over the last three months. Insiders own 7.30% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of SYK. ETRADE Capital Management LLC boosted its stake in shares of Stryker by 4.7% in the 4th quarter. ETRADE Capital Management LLC now owns 10,809 shares of the medical technology company’s stock valued at $1,694,000 after purchasing an additional 481 shares during the last quarter. Noesis Capital Mangement Corp boosted its stake in shares of Stryker by 0.4% in the 4th quarter. Noesis Capital Mangement Corp now owns 64,148 shares of the medical technology company’s stock valued at $10,055,000 after purchasing an additional 228 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Stryker by 4.1% in the 4th quarter. BlackRock Inc. now owns 24,882,912 shares of the medical technology company’s stock valued at $3,900,399,000 after purchasing an additional 975,678 shares during the last quarter. Utah Retirement Systems boosted its stake in shares of Stryker by 0.3% in the 4th quarter. Utah Retirement Systems now owns 63,678 shares of the medical technology company’s stock valued at $9,982,000 after purchasing an additional 200 shares during the last quarter. Finally, Trillium Asset Management LLC boosted its stake in shares of Stryker by 3.4% in the 4th quarter. Trillium Asset Management LLC now owns 18,810 shares of the medical technology company’s stock valued at $2,948,000 after purchasing an additional 626 shares during the last quarter. 73.38% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:SYK traded up $1.91 during midday trading on Friday, hitting $182.66. The stock had a trading volume of 1,317,710 shares, compared to its average volume of 1,697,556. The stock has a market capitalization of $67.63 billion, a PE ratio of 24.99, a PEG ratio of 2.22 and a beta of 0.86. The company has a current ratio of 2.02, a quick ratio of 1.21 and a debt-to-equity ratio of 0.72. Stryker has a fifty-two week low of $144.75 and a fifty-two week high of $182.69.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 29th. The medical technology company reported $2.18 EPS for the quarter, beating the consensus estimate of $2.15 by $0.03. The company had revenue of $3.80 billion during the quarter, compared to analysts’ expectations of $3.73 billion. Stryker had a net margin of 26.12% and a return on equity of 27.60%. On average, research analysts predict that Stryker will post 8.12 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date of this dividend is Thursday, March 28th. Stryker’s payout ratio is 28.45%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: No Load Funds

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply